Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta
Introduction: Pegylated-interferon alpha (Peg-IFN α) is the therapy most commonly used to treat chronic hepatitis delta virus (HDV) infection. In the present study, we planned to investigate effect of IL28B polymorphism on response to Peg-IFN α therapy and disease progression in patients with chroni...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2017-01-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/6872 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850035860067581952 |
|---|---|
| author | Murat Ispiroglu Ibrahim Halil Bahcecioglu Ulvi Demirel Mehmet Yalniz |
| author_facet | Murat Ispiroglu Ibrahim Halil Bahcecioglu Ulvi Demirel Mehmet Yalniz |
| author_sort | Murat Ispiroglu |
| collection | DOAJ |
| description | Introduction: Pegylated-interferon alpha (Peg-IFN α) is the therapy most commonly used to treat chronic hepatitis delta virus (HDV) infection. In the present study, we planned to investigate effect of IL28B polymorphism on response to Peg-IFN α therapy and disease progression in patients with chronic HDV.
Methodology: A total of 47 patients who received Peg-IFNα therapy for at least one year were investigated. The patients were divided into three groups based on their response to treatment: sustained viral response (SVR) (32%), unresponsive (53%), and relapse (15%). The groups were compared in terms of age, gender, blood biochemistry (albumin, total bilirubin, lactic acid dehydrogenase, ALT, AST, ALP, GGT), complete blood count, HBeAg, HBsAg, HBV-DNA, HDV-RNA, IL28B genotypes (CC, CT, TT), and results of liver biopsy.
Results: Regarding the investigation of IL28B genotype, the prevalence of CC, CT, and TT showed no difference among the three groups. In the SVR group, the prevalence of CC was 53%, CT was 47%, but there was no patient with TT. In the unresponsive group, prevalence of CC was 52%, CT was 32%, and TT was 16%. In the relapse group, prevalence of CC was 43%, CT was 57%, but there was no patient with TT genotype. No significant difference was found among the groups with sustained response, no response, and relapse in terms of CC and CT polymorphisms (p>0.05).
Conclusions: No relationship was found between IL28B rs12979860 polymorphism and response to treatment and disease severity in patients with chronic HDV infection.
|
| format | Article |
| id | doaj-art-eaaebd51eae94f1eaba8b76f1ecf508b |
| institution | DOAJ |
| issn | 1972-2680 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-eaaebd51eae94f1eaba8b76f1ecf508b2025-08-20T02:57:21ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802017-01-01110110.3855/jidc.6872Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis deltaMurat Ispiroglu0Ibrahim Halil Bahcecioglu1Ulvi Demirel2Mehmet Yalniz3Faculty of Medicine, Firat University, Elazig, TurkeyFaculty of Medicine, Firat University, Elazig, TurkeyFaculty of Medicine, Firat University, Elazig, TurkeyFaculty of Medicine, Firat University, Elazig, TurkeyIntroduction: Pegylated-interferon alpha (Peg-IFN α) is the therapy most commonly used to treat chronic hepatitis delta virus (HDV) infection. In the present study, we planned to investigate effect of IL28B polymorphism on response to Peg-IFN α therapy and disease progression in patients with chronic HDV. Methodology: A total of 47 patients who received Peg-IFNα therapy for at least one year were investigated. The patients were divided into three groups based on their response to treatment: sustained viral response (SVR) (32%), unresponsive (53%), and relapse (15%). The groups were compared in terms of age, gender, blood biochemistry (albumin, total bilirubin, lactic acid dehydrogenase, ALT, AST, ALP, GGT), complete blood count, HBeAg, HBsAg, HBV-DNA, HDV-RNA, IL28B genotypes (CC, CT, TT), and results of liver biopsy. Results: Regarding the investigation of IL28B genotype, the prevalence of CC, CT, and TT showed no difference among the three groups. In the SVR group, the prevalence of CC was 53%, CT was 47%, but there was no patient with TT. In the unresponsive group, prevalence of CC was 52%, CT was 32%, and TT was 16%. In the relapse group, prevalence of CC was 43%, CT was 57%, but there was no patient with TT genotype. No significant difference was found among the groups with sustained response, no response, and relapse in terms of CC and CT polymorphisms (p>0.05). Conclusions: No relationship was found between IL28B rs12979860 polymorphism and response to treatment and disease severity in patients with chronic HDV infection. https://jidc.org/index.php/journal/article/view/6872Delta hepatitisinterleukin 28Binterferon |
| spellingShingle | Murat Ispiroglu Ibrahim Halil Bahcecioglu Ulvi Demirel Mehmet Yalniz Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta Journal of Infection in Developing Countries Delta hepatitis interleukin 28B interferon |
| title | Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta |
| title_full | Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta |
| title_fullStr | Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta |
| title_full_unstemmed | Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta |
| title_short | Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta |
| title_sort | impact of interleukin 28b rs12979860 c t polymorphism on severity of disease and response to treatment in hepatitis delta |
| topic | Delta hepatitis interleukin 28B interferon |
| url | https://jidc.org/index.php/journal/article/view/6872 |
| work_keys_str_mv | AT muratispiroglu impactofinterleukin28brs12979860ctpolymorphismonseverityofdiseaseandresponsetotreatmentinhepatitisdelta AT ibrahimhalilbahcecioglu impactofinterleukin28brs12979860ctpolymorphismonseverityofdiseaseandresponsetotreatmentinhepatitisdelta AT ulvidemirel impactofinterleukin28brs12979860ctpolymorphismonseverityofdiseaseandresponsetotreatmentinhepatitisdelta AT mehmetyalniz impactofinterleukin28brs12979860ctpolymorphismonseverityofdiseaseandresponsetotreatmentinhepatitisdelta |